Search
You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "pharmaceuticals."
12 result(s) displayed (1 - 12 of 44)
More than a year after announcing that it would split off from Abbott Laboratories, the research-based pharmaceutical company's stock finally started trading Wednesday. Continue reading
Posted on January 2, 2013 3:45 PM
After years of being a top dealmaker, Abbott is doing its biggest deal yet as it breaks itself in two. Continue reading
Posted on November 19, 2012 12:15 PM
The London buyout shop will make at least 4.1 times its original investment in selling the company to Cinven for $731 million. Continue reading
Posted on August 17, 2012 2:15 PM
Pfizer has made a $250 million move to bolster its consumer healthcare division through an agreement with AstraZeneca that could begin a larger relationship between the drugmakers Continue reading
Posted on August 15, 2012 4:33 PM
Analysts and investors think the generics maker could command a higher price. Continue reading
Posted on July 17, 2012 1:12 PM
New, creative financing deals among financiers, big pharmas and biotech entrepreneurs are promising to rejuvenate the search for new drugs. Continue reading
Posted on July 13, 2012 12:02 PM
For the second time in two years, Carl Icahn is going directly after Forest Laboratories Inc. CEO Howard Solomon. Continue reading
Posted on June 29, 2012 2:54 PM
Healthcare-focused Water Street could gain as much as a 2.4 times return from the sale of the dental-health company. Continue reading
Posted on June 18, 2012 10:57 AM
The Deal Pipeline's David Holley discusses the steps that the city of Kalamazoo, Mich.'s venture capitalists and business leaders have taken to ensure the pharmaceutical and biotech sectors continue to thrive there. Continue reading
Posted on June 5, 2012 4:29 PM
The expiration of blockbuster drug patents and the melding of generic and branded drug makers has become one of the driving forces for M&A, according to Jenner & Block's Kevin Collins. Continue reading
Posted on May 9, 2012 4:00 AM
The expiration of blockbuster drug patents and the melding of generic and branded drug makers has become one of the driving forces for M&A, according to Jenner & Block's Kevin Collins. Continue reading
Posted on May 8, 2012 11:52 AM
Movable Type search results powered by Fast Search
NBGI Private Equity appointed food and drinks industry veteran Tim Kelly as a senior adviser. For other updates launch today's Movers & shakers slideshow.
Blackstone Real Estate and DDR divide 46 shopping centers in a $1.46 billion deal. More video
